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ABSTRACT
Background: Readmission rates following hospitalisation for COPD exacerbations are unacceptably high,
and the contributing factors are poorly understood. Our objective was to summarise and evaluate the
factors associated with 30- and 90-day all-cause readmission following hospitalisation for an exacerbation
of COPD.
Methods: We systematically searched electronic databases from inception to 5 November 2019. Data were
extracted by two independent authors in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. Study quality was assessed using a modified version of
the Newcastle–Ottawa Scale. We synthesised a narrative from eligible studies and conducted a meta-
analysis where this was possible using a random-effects model.
Results: In total, 3533 abstracts were screened and 208 full-text manuscripts were reviewed. A total of 32
papers met the inclusion criteria, and 14 studies were included in the meta-analysis. The readmission rate
ranged from 8.8–26.0% at 30 days and from 17.5–39.0% at 90 days. Our narrative synthesis showed that
comorbidities, previous exacerbations and hospitalisations, and increased length of initial hospital stay
were the major risk factors for readmission at 30 and 90 days. Pooled adjusted odds ratios (95%
confidence intervals) revealed that heart failure (1.29 (1.22–1.37)), renal failure (1.26 (1.19–1.33)),
depression (1.19 (1.05–1.34)) and alcohol use (1.11 (1.07–1.16)) were all associated with an increased risk
of 30-day all-cause readmission, whereas being female was a protective factor (0.91 (0.88–0.94)).
Conclusions: Comorbidities, previous exacerbations and hospitalisation, and increased length of stay were
significant risk factors for 30- and 90-day all-cause readmission after an index hospitalisation with an
exacerbation of COPD.
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Introduction
Exacerbations of COPD are a major cause of hospitalisation and mortality [1, 2]. According to the Global
Burden of Disease study [1], there were 251 million cases of COPD worldwide in 2016. An estimated 3.17
million deaths were caused by COPD in 2015, accounting for 5% of all global deaths, and projections
suggest that COPD will soon be the third leading cause of death worldwide [1]. COPD is punctuated by
periodic deteriorations in respiratory symptoms called exacerbations; exacerbations cause most of the
hospitalisations, with significant effects on morbidity and mortality [3].
For patients surviving hospitalisation with a COPD exacerbation, readmission to hospital is a major
problem. Identifying and mitigating risk factors for readmission is therefore important [4, 5]. In the USA,
around 19% of COPD patients are readmitted within 30 days, while in the UK the all-cause readmission
rates are 24% within 30 days and 43% within 90 days of discharge [5, 6]. Data from the European COPD
Audit show that the risk of in-hospital mortality was substantially higher in readmitted patients compared
to non-readmitted patients (13.4% versus 2.3%) [7]. Differences in readmission rates have been associated
with unexplained variations in care quality [8]. In the USA, the Centers for Medicare and Medicaid
Services have applied financial penalties to hospitals that have high readmission rates and have considered
readmissions a marker of the quality of care [9, 10]. Similar penalties have been applied in the British
NHS in an attempt to reduce readmission rates and improve quality of care [11]. Globally, preventing
readmissions among patients with COPD following acute exacerbations has been recognised as a
high-priority management strategy [12]. Recently, the official American Thoracic Society workshop report
on reducing COPD readmission emphasised the need for improvements in identifying risk factors for
COPD readmissions [13].
Reflecting the importance of readmissions to patients, clinicians and payers, there has been considerable
research assessing the risk factors that lead to readmissions. However, whilst there was a 2007 systematic
review examining risk factors for COPD-related readmissions [14], there is no existing review investigating
risk factors for all-cause COPD readmission. Therefore, the purpose of this systematic review was to
evaluate and summarise the risk factors for all-cause hospital readmissions in patients admitted for COPD
exacerbations, and to identify areas of research to mitigate such risk.
Methods
Protocol and registration
This systematic review was conducted in accordance with the Preferred Reporting in Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [15] and the review was prospectively registered on PROSPERO
(identifier CRD42019119364).
Search strategy
We searched MEDLINE, Embase, CINAHL and Scopus from inception to 5 November 2019. We used an
extensive search strategy developed for retrieving this type of evidence, which included the reference list of
eligible papers (tables S1 and S2).
Inclusion criteria
The PICO framework was used in our search strategy: P: population (COPD patients admitted due to
COPD exacerbation); I: intervention (not applicable); C: comparison (patients get readmitted versus not
readmitted); O: outcome (readmission within 30 and 90 days). We included studies that investigated: 1)
readmission/rehospitalisation after an initial admission with COPD exacerbation; 2) all-cause readmission
defined as any emergency (non-elective) readmission to hospital; and 3) studies that investigated all-cause
readmissions and analysed the contribution of risk factors and/or predictors associated with readmission/
rehospitalisation.
Exclusion criteria
We excluded the following: 1) studies that examined readmission risk >1 year after discharge from index
admission; 2) intervention studies that did not include examination of risk factors for all-cause hospital
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readmission for patients with COPD in the control group; 3) studies that included factors/predictors/
causes for readmission but did not specifically analyse all-cause COPD readmission-related factors; 4)
conference abstracts, editorial reports, correspondence, reviews, qualitative studies and theses; 5)
non-English manuscripts; and 6) non-full-text articles.
Data collection
Two authors ( J.S. Alqahtani and J.R. Hurst) independently screened titles and abstracts of potential studies
and conflicts were resolved through a discussion with a third author (S. Mandal). Full-text articles of
potential studies were then independently read by two authors ( J.S. Alqahtani and C.M. Njoku) to identify
studies meeting the inclusion criteria. The reference lists from all identified studies and reviews were
scrutinised for eligible articles. Disagreement on selected papers was resolved through discussion with a
third author ( J.R. Hurst).
Quality assessment
Two authors independently evaluated the methodological quality of included studies using a modified
version of the Newcastle–Ottawa Scale [16]. This scale utilises a “star” system with a maximum score of
nine stars for each study. Study ratings are categorised as good (7–9 stars), fair (4–6 stars) or poor (1–3
stars). Any disagreement in the quality assessment was resolved by discussion with a third author
(supplementary material).
Data synthesis
We were not able to perform a meta-analysis on all results because of the heterogeneity of included studies
and inconsistencies in reporting risk factors across studies. However, we did conduct a meta-analysis using
summary data from 14 studies to synthesise adjusted odds ratios for risk factors where results were
reported consistently (for example, similar age ranges) and where a variable was reported in at least four
studies in total. To account for study heterogeneity, we used the random-effects model in Stata 14.0
(StataCorp LLC, College Station, TX, USA). Data are displayed using forest plots. We examined
between-study heterogeneity using the I2 statistic. A narrative synthesis of the results was conducted,
guided by study quality.
Results
An initial search generated 3533 potentially relevant papers, of which 1657 were immediately excluded due
to duplication. After the first screening of title and abstract, 208 papers were potentially relevant according
to the inclusion criteria. An additional 176 papers were excluded after full-text review, which resulted in
32 studies that satisfied all criteria. The reference list of the relevant papers was also examined and did not
result in any new papers (figure 1).
Description of included studies
A summary of the included studies is presented in table 1, Out of 32 studies, 27 were conducted
retrospectively and five were conducted prospectively; 21 studies were conducted in the USA, three in the
UK, two in Canada and one each in Spain, Korea, Hong Kong, Israel, Australia and Europe. All papers
were published between 2013 and 2019, and included a total of 3982881 patients. Among the 32 studies,
three were rated as “fair” in the quality assessment. The remaining papers were ranked as “good” quality.
A detailed description of the studies is presented in table S3. The all-cause readmission rates ranged from
8.8% to 26.0% at 30 days, 17.5% to 39.0% at 90 days, and from 8.8% to 65.2% at 1 year. Studies described
several risk factors for all-cause COPD readmission at different time-points, the results of which are
summarised in figure 2 and table S4. The details of all risk factors and the quality assessment of each
study are presented in tables S3 and S5.
Meta-analysis results
We conducted a meta-analysis on 14 studies examining five risk/protective factors associated with all-cause
30-day readmission, including a total of 3792506 patients, which represents ∼95% of the total sample size
of the included papers. These studies were included because the reported risk factors in such studies were
consistent among them. This included 2442314 participants in eight studies that reported heart failure as
a risk factor, 2349651 in six studies that reported depression as a risk factor, 2331529 in six studies that
reported alcohol use as a risk factor, 2261874 in four studies that reported renal failure as a risk factor
and 3506458 in nine studies that found that female sex was a protective factor. There was heterogeneity
between studies with significant I2 values that ranged from 59.8% to 96.7%; therefore, we calculated the
pooled adjusted odds ratio values using a random-effect model. There was no adjustment for forced
expiratory volume in 1 s in the selected odds ratios because there were no confirmatory spirometry values
available to clinicians at the time of management. The pooled adjusted odds ratios for heart failure, renal
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failure, depression, alcohol use and female sex are presented using forest plots (figures 3–7). Heart failure
was associated with the highest odds of readmission followed by renal failure, then depression.
In general, the significant risk factors for 30- and 90-day all-cause readmission were comorbidities,
previous exacerbations and hospitalisations, and increased length of initial hospital stay. A narrative
synthesis of the 30-day studies appears below, with further detail on the 90-day studies included in the
supplementary material.
Narrative synthesis: risk factors for all-cause readmission at 30 days
Comorbidities
Overall, 17 out of 32 studies reported various comorbidities as significant risk factors for 30-day
readmission, with heart failure, depression and renal failure included in our meta-analysis. Many other
comorbidities were also reported (tables S2 and S3). Four studies [22, 38, 43, 47] used the comorbidity
index to assess comorbidities. SPECE et al. [47] found that each one-point increase in comorbidity index
was associated with a 24% increased risk of readmission or death: OR 1.24 (95% CI 1.18–1.30).
Previous COPD exacerbations and hospitalisations
Previous exacerbations and hospitalisations were risk factors for 30-day readmission in nine studies. An
emergency room visit in the previous 6 months (1 versus 0) was associated with increased readmission risk
with OR 1.90 (95% CI 1.01–3.58) in the study by BASHIR et al. [19] and OR 1.25 (95% CI 1.21–1.29) in the
study by HAKIM et al. [33]. The risk of readmission increased with a greater number of previous emergency
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FIGURE 1 Flow diagram of studies included in the review based on the Preferred Reporting Items for
Systematic Review and Meta-Analysis Guidelines.
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TABLE 1 Characteristics of the included studies, with quality assessment
First author
[ref.]
Study
design Sample size Age years
GOLD
severity
Readmission
time
Causes and rates of readmission, in
order of prevalence
Study
quality
ALMAGRO [17] P Total:
n=983
M: n=899
(92%)
F: n=84 (8%)
72.25±9.7 GOLD 3 90 day and
1 year
All readmission at 90 days: 34.2%
All readmission at 1 year: 53.8%
Good
BAKER [18] R Total:
n=6095
M: n=2499
(40.8%)
F: n=3596
(59.2%)
40–65 Not
reported
1, 3 and
12 months
All readmission at 30 days: 8.3%
67.6% readmitted for COPD
32.2% non-COPD
All readmission at 90 days: 17.5%
67% were readmitted for COPD
33% non-COPD
All readmission at 1 year: 41.5%
66.5% readmitted for COPD
33.5% non-COPD
Good
BASHIR [19] R Total:
n=461
M: n=311
(67.5%)
F: n=150
(32.5%)
71.7±13.3 Not
reported
30 days Overall rate: 16.5% Good
BOLLU [20] R Total:
n=2463
M: n=1054
(43%)
F: n=1409
(57%)
72.5±12 Not
reported
30 days Overall rate: 20.6%
Rate in arformoterol patients (8.7%)
Rate in nebulised SABA patients (11.9%)
Good
BOTTLE [21] R Total: n=96
053
M: n=46388
(48.3%)
F: n=49665
(51.7%)
36-⩾85 Not
reported
30 days Overall rate: 16.5%
Non-COPD (60.9%)
COPD related (39.1%)
Good
CANDRILLI
[22]
R Total: n=264
526
M: n=129769
(49%)
F: n=134757
(51%)
30 days=67.69
±11.26
90 days=67.42
±11.23
Not
reported
30 days and
90 days
Overall rate at 30 days: 19.82%
Overall rate at 90 days: 28.31%
Good
CHAN [23] R Total: n=65
497
M: n=50456
(77%)
F: n=15041
(23%)
76.81±9.6 Not
reported
30 days Overall rate: 24.2% Good
CHAWLA [24] P Total:
n=54
M: n=30
(55%)
F: n=24 (45%)
70±12 GOLD 3 30 days Overall rate: 26% Fair
CHOI [25] R Total:
n=704
M: n=492
(70%)
F: n=212 (30%)
72.4±9.5 GOLD 2–3 30 days Overall rate: 9.3% Good
Continued
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TABLE 1 Continued
First author
[ref.]
Study
design
Sample size Age years GOLD
severity
Readmission
time
Causes and rates of readmission, in
order of prevalence
Study
quality
COUILLARD
[26]
R Total:
n=167
M: n=86
(51.5%)
F: n=81 (48.5%)
71.4±10.3 GOLD 2 1 year Overall rate: 58% Good
ECHEVARRIA
[27]
P Total:
n=2417
M: n=1119
(46%)
F: n=1298
(54%)
72.5±10.1 GOLD 3 90 day Overall rate: 39% Good
EPSTEIN [28] R Total:
n=539
M: n=325
(60%)
F: n=214 (40%)
69.19±11.75 Not
reported
60 day Overall rate: 26.35%
Non-COPD (58.45%)
Due to AECOPD (41.55%)
Good
EHSANI [29] P Total:
n=42
M: n=28
(66.7%)
F: n=14 (33.3%)
70±8.6 Not
reported
30 day Overall rate: 9.5% Fair
GENAO [30] R Total: n=52
741
M: n=23397
(44%)
F: n=29344
(56%)
71.4±10.3 Not
reported
30 day, 1 year
and 3 years
Overall rate at 30 days: 25.5%
Overall rate at 1 year: 73%
COPD (AECOPD) (20%)
Pneumonia (7.22%)
Heart failure (4.64%)
Respiratory failure (3.5%)
Chest pain (2.8%)
Others (61.84%)
Good
GOTO [31] R Total: n=845
465
M: n=350967
(41%)
F: n=494498
(59%)
69±0.01 Not
reported
30 days Overall rate: 19.7% Good
GERSHON [32] R Total: n=126
013
M: not
presented
F: not
presented
35–85+ Not
reported
30 days Overall rate: 19.4%
Due to COPD (61.9%)
Non-COPD (38.1%)
Good
HAKIM [33] R Total:
n=2662
M: n=1418
(53%)
F: n=1244(47%)
72.5±12 Not
reported
30 days and
1 year
Overall rate at 30 days: 25.1%
Non-COPD (44%); heart failure,
pneumonia, chest pain, MI, cellulitis,
asthma and others
COPD related (56%)
Overall rate at 1 year: 65.2%
Non-COPD (48%); heart failure, chest
pain, pneumonia, MI, asthma,
cellulitis, and others
COPD related (52%)
Fair
HIJJAWI [34] P Total:
n=160
M: n=76
(47.5%)
F: n=84 (52.5%)
65.77±12.47 GOLD 1–4 30 days Overall rate at 30 days (19.4%)
COPD (51.4%)
Pneumonia (16.2%)
Congestive heart failure (2.7%)
Others (51.4%)
Good
Continued
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TABLE 1 Continued
First author
[ref.]
Study
design
Sample size Age years GOLD
severity
Readmission
time
Causes and rates of readmission, in
order of prevalence
Study
quality
JACOBS [35] R Total: n=1055
830
M: n=437812
(41%)
F: n=618018
(59%)
68 (58–77) Not
reported
3, 7 and
30 days
Overall rate at 30 days: 19.2%
At 3 days: 14.4% of 30-day readmissions
At 7 days: 30% of 30-day readmissions
At 15 days: 58% of 30-day readmissions
COPD and bronchiectasis (28.36%)
Respiratory failure (9.47%)
Pneumonia (7.64%)
Asthma (6.97%)
Congestive heart failure (5.80%)
Septicaemia (5.72%)
Cardiac dysrhythmias (2.44%)
Acute and unspecified renal failure
(1.52%)
Acute MI (1.12%)
Fluid and electrolyte disorders
(1.10%)
Good
KON [36] P Total:
n=213
M: n=111
(52%)
F: n=102 (48%)
72.1±10.8 GOLD 3 90 days Overall rate: 27.7%
Respiratory causes (80%)
Nonrespiratory causes (20%)
Good
LOH [37] R Total:
n=123
M: n=65
(52.8%)
F: n=58 (47.2%)
64.9±11.3 GOLD 3 30 and
90 days
Overall rate at 30 days: 12.2%
Overall rate at 90 days: 32.5%
52% (64 out of 123) had suboptimal
PIF
17.2% (11 out of 64) readmitted
within 30 days
39.1% (25 out of 64) readmitted
within 90 days
Good
NGUYEN [38] R Total:
n=4596
M: n=2040
(44%)
F: n=2556
(56%)
72.3±11 GOLD 2 30 days Overall: 18%
Non-COPD (55%); other respiratory/
ventilator disorders, pneumonia,
gastrointestinal disorders, sepsis/
shock, heart failure, arrhythmias/
conduction disorders, renal
disorders, acute MI, electrolyte
disturbances, and nutrition/metabolic
disorders
Due to AECOPD (45%)
Good
NGUYEN [39] R Total:
n=2910
M: n=1248
(43%)
F: n=1662
(57%)
72±11 GOLD 2 30 days Overall rate: 23% Good
RINNE [40] R Total: n=20
472
M: not
presented
F: not
presented
73 Not
reported
30 days Overall rate: 20.2%
Non-COPD (54%)
COPD related (46%)
Good
RINNE [41] R Total: n=33
558
M: n=32417
(96.6%)
F: n=1141
(3.4%)
68.7 Not
reported
30 days Overall rate: 18% Good
Continued
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TABLE 1 Continued
First author
[ref.]
Study
design
Sample size Age years GOLD
severity
Readmission
time
Causes and rates of readmission, in
order of prevalence
Study
quality
ROBERTS [42] R Total:
n=306
M: n=135
(44%)
F: n=171 (56%)
71 Not
reported
30 and
90 days
Overall rate at 30 days: 9.2%
Non-COPD (50%)
Respiratory related (50%)
Overall rate at 90 days: 20.3%
Good
SHAH [43] R Total: n=947
084
M: n=392187
(41.41%)
F: n=554897
(58.59%)
73.55±10.87 Not
reported
30 days Overall rate: 20.2%
Non-COPD (49.4%)
Respiratory related (50.6%)
Good
SHARIF [44] R Total:
n=8263
M: n=3401
(41%)
F: n=4862
(59%)
56.55±5.73 Not
reported
30 days Overall rate: 8.9%
COPD (27.4%)
Respiratory failure (14.3%)
Symptoms involving respiratory
system (8.5%)
Pneumonia (4.2%)
Heart failure (2.3%)
Cardiac dysrhythmia (2.2%)
Coronary atherosclerosis (2.0%)
Lung cancer (1.8%)
Septicaemia (1.6%)
Acute pulmonary heart disease (0.9%)
Other (34.8%)
Good
SIMMERING
[45]
R Total: n=286
313
M: n=130497
(45.5%)
F: n=155816
(54.5%)
40–90+ Not
reported
30 days Overall rate: 12.2% Good
SINGH [46] R Total: n=135
498
M: n=53940
(38.80%)
F: n=81558
(62%)
66–74,
75–84, ⩾85
Not
reported
30 days Overall rate: 18%
22.30% patients had one or more
coexisting psychological disorders
30-day readmission rate for patients
with COPD with coexisting psychological
disorders (23.80%)
30-day readmission rate for patients
with COPD without coexisting
psychological disorders (16.25%)
Main reasons:
COPD (30.89%)
Pneumonia (10.62%)
Heart failure (6.55%)
Good
SPECE [47] R Total:
n=2391
M: n=2319
(97%)
F: n=72 (3%)
68.0±10.4 Not
reported
30 days Overall rate: at 30 days: 16%
COPD (36%)
Cardiac diseases (12%)
Others (52%)
Good
TZY-CHYI YU
[48]
R Total: n=18
282
M: n=6869
(37.6%)
F: n=11413
(62.4%)
56.6±5.8 Not
reported
30 days Overall rate: 15.50%
Non-COPD (47%)
COPD as any diagnosis (36%)
COPD as primary diagnosis (17%)
Good
Data are presented as mean±SD or range, unless otherwise stated. GOLD: The Global Initiative for Chronic Obstructive Lung Disease; P:
prospective; R: retrospective; M: male; F: female; SABA: short-acting beta agonist; AECOPD: acute exacerbations of COPD; MI: myocardial
infarction; PIF: peak inspiratory flow.
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room visits (⩾4 versus 0) with OR 4.37 (95% CI 1.83–10.46) and OR 2.31 (95% CI 2.23–2.39) [19, 32].
Previous COPD and non-COPD hospitalisations in the previous year also significantly increased the risk
for 30-day readmission by 53% to 56% and 60% to 64%, respectively [38, 39]. Consistent with other
studies, GOTO et al. [31] found that frequent exacerbators (defined as two hospitalisations in the past year)
Previous exacerbations and hospitalisation
Comorbidities
Increased length of stay
Sex
Behavioural and social factors
Discharge location
COPD severity
Age
ICU admission
Type of insurance
Ethnicity
Oxygen use (at admission or at discharge)
Corticosteroid use (inhaled or oral)
Physical activity
Hospital size and type
Weather
Acidosis (pH <7.35 before discharge)
Pseudomonas in sputum
Studies with a significant finding
Studies without a significant finding
50
Studies n
10 15 20 25
FIGURE 2 Summary of risk/predictive factors associated with 30- and 90-day all-cause hospital readmission following a hospitalised exacerbation
of COPD by order of total number of studies in which there was a significant finding. ICU: intensive care unit.
First author [ref.] OR (95% CI) Weight %
BAKER [18]
BOTTLE [21]
GERSHON [32]
GOTO [31]
JACOBS [35]
SHARIF [44]
SIMMERING [45]
TZY-CHYI YU [48]
Overall (I2=95.4%, p=0.000)
1.41 (1.11–1.78)
1.19 (1.12–1.26)
1.22 (1.18–1.25)
1.41 (1.39–1.43)
1.28 (1.26–1.31)
1.20 (1.00–1.50)
1.25 (1.22–1.29)
1.51 (1.33–1.71)
1.29 (1.22–1.37)
3.97
14.95
16.52
16.91
16.80
6.02
16.52
8.29
100
Doesn’t favour readmission Favours readmission
0–1.78 1 1.78
FIGURE 3 Pooled adjusted odds ratios (ORs) for heart failure. This is a forest plot examining eight studies and
risk of 30-day readmission using random effects analysis.
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had a 2.5-fold increase in odds of readmission compared to non-frequent exacerbators. Disease severity of
COPD was also a risk factor for readmission and has been evaluated using different tools. These included
the LACE Index [19], the 3 M™ All Patient Refined™ Diagnosis-Related Groups (APR-DRG)
classification tool [20, 42] and a COPD complexity tool [22]. Using long-term systemic corticosteroids was
a risk factor for readmission, with 49% increased risk in one study [38]. However, receiving oral
corticosteroids at discharge decreased the odds of readmission by 72% and 30% [42, 44]. The differences
between use of corticosteroids in the immediate post-discharge period and longer term requires further
study. The severity of an exacerbation is the composite of the severity of the insult and the severity of the
underlying COPD. Intensive care unit admission was also associated with increased risk of re-admission in
six studies. These patients are also likely to have longer lengths of stay.
Patient demographics
Different age groups were found to be at different risk of readmission in six studies, but results were
inconsistent. Older patients with COPD typically had a greater likelihood of being readmitted (table S3).
Ethnicity was investigated in nine studies with results that were also inconsistent (table S3).
Behavioural risk factors
Physical activity was examined in four studies, and low activity was reported to be a significant risk factor
for 30-day readmission in three studies. For example, NGUYEN et al. [39] reported that those with low-level
functioning within 24 h of discharge (levels I–III (bed bound, able to sit or can stand) versus level V
First author [ref.] OR (95% CI) Weight %
BOTTLE [21]
CANDRILLI  [22]
GOTO [31]
JACOBS [35]
Overall (I2=93%, p=0.000)
1.21 (1.13–1.28)
1.37 (1.32–1.43)
1.27 (1.24–1.29)
1.19 (1.17–1.22)
1.26 (1.19–1.33)
21.37
24.08
27.28
27.28
100
Doesn’t favour readmission Favours readmission
0–1.43 1 1.43
FIGURE 4 Pooled adjusted odds ratio (ORs) for renal failure. This is a forest plot examining four studies and
risk of 30-day readmission using random effects analysis.
First author [ref.] OR (95% CI) Weight %
GOTO [31]
JACOBS [35]
SHARIF [44]
SIMMERING [45]
SINGH [46]
TZY-CHYI YU [48]
Overall (I2=98.7%, p=0.000)
1.27 (1.24–1.29)
1.00 (0.98–1.02)
1.30 (1.10–1.80)
1.04 (1.00–1.07)
1.34 (1.29–1.39)
1.30 (1.12–1.49)
1.19 (1.05–1.34)
19.24
19.28
8.89
19.13
18.90
14.57
100
Doesn’t favour readmission Favours readmission
0–1.8 1 1.8
FIGURE 5 Pooled adjusted odds ratio (ORs) for depression. This is a forest plot examining six studies and risk
of 30-day readmission using random effects analysis.
https://doi.org/10.1183/16000617.0166-2019 10
COPD | J.S. ALQAHTANI ET AL.
(walks >50 feet)) were more likely to be readmitted with a relative risk of 2.14 and that patients who
engaged in moderate to strenuous exercise with 1–149 min·week−1 or ⩾150 min·week−1 post-discharge
were 33–34% less at risk for readmission compared to inactive patients [38]. Alcohol use was the most
frequently reported social risk factor in six papers [31, 34, 35, 44–46] and has been included in our
meta-analysis. SINGH et al. [46] and GERSHON et al. [32] identified low socioeconomic status as a significant
risk factor with a 22% and 6% increased risk of readmission, respectively.
Health system-related risk factors
Length of stay (LOS) was reported to be a significant risk factor for 30-day readmission; whilst in general a
longer LOS was associated with increased risk of readmission, some studies found patients with the
First author [ref.] OR (95% CI) Weight %
BASHIR [19]
BOLLU [20]
BOTTLE [21]
CANDRILLI [22]
GOTO [31]
JACOBS [35]
SHAH [43]
SHARIF [44]
SIMMERING [45]
Overall (I2=91.3%, p=0.000)
0.51 (0.29–0.91)
0.85 (0.66–1.11)
0.90 (0.87–0.93)
1.02 (0.99–1.05)
0.91 (0.90–0.92)
0.87 (0.85–0.88)
0.89 (0.88–0.90)
0.90 (0.70–0.90)
0.91 (0.89–0.93)
0.91 (0.88–0.94)
0.67
1.23
13.96
13.96
16.76
16.25
16.76
4.82
15.59
100
Doesn’t favour readmission Favours readmission
0–1.2 1 1.2
FIGURE 7 Pooled adjusted odds ratio (ORs) for female sex. This is a forest plot examining nine studies and
risk of 30-day readmission using random effects analysis.
First author [ref.] OR (95% CI) Weight %
GOTO [31]
HIJJAWI [34]
JACOBS [35]
SHARIF [44]
SIMMERING [45]
SINGH [46]
Overall (I2=59%, p=0.029)
1.08 (1.04–1.11)
2.17 (1.16–4.09)
1.13 (1.09–1.16)
1.10 (0.90–1.30)
1.08 (1.03–1.14)
1.30 (1.15–1.47)
1.11 (1.07–1.16)
31.57
0.10
31.57
4.76
25.03
6.96
100
Doesn’t favour readmission Favours readmission
0–4.09 1 4.09
FIGURE 6 Pooled adjusted odds ratio (ORs) for alcohol use. This is a forest plot examining six studies and risk
of 30-day readmission using random effects analysis.
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shortest LOS were at higher risk than those who stayed slightly longer. For example, compared to 1–
3 days, CANDRILLI et al. [22] found patients who stayed for >10 days or for 8–10 days had increased odds of
readmission by 64% and 25%, respectively, but there was 18% reduced odds of readmission for those who
stayed for 4–7 days. In the study by JACOBS et al. [35], those hospitalised for >5 days versus ⩽2 days had an
OR of 1.32 (95% CI 1.29–1.34). Furthermore, in two studies [38, 39], LOS ⩾14 days versus 1–2 days
increased the relative risk of readmission 2.93-fold and 2.85-fold, respectively. GERSHON et al. [32] found an
OR of 1.18 when LOS was ⩾14 days compared to 4–6 days but found that this risk decreased to 66% and
37% when the LOS was 7–13 and 4–6 days, respectively [38]. RINNE et al. [41] found that those with LOS
of 3–4 days and >4 days had higher odds of readmission at 39% and twofold, respectively, compared to
<3 days. SIMMERING et al. [45] found an OR of 1.16 with patients who stayed for >1 day and SINGH et al.
[46] found that the odds increased to 1.47 when LOS was >7 days. When >7 days was compared to 3–
4 days in the study by SHARIF et al. [44], the readmission OR reduced to 1.20, but the odds increased to
1.30 when 1–2 days was compared to 3–4 days.
Discharge destination was found to be a significant risk factor for readmission in nine studies but is
probably complex because of confounding with disease severity and comorbidity. Compared to discharge
to home with no home care, discharge to a skilled nursing facility increased readmission in three studies
[19, 35, 43] by three-fold, 42% and 28%, respectively. Only one study [46] reported this as a protective
factor with an OR of 0.84. Additionally, when discharged to home with care, the odds of readmission
increased by 30%, 36%, 32% and 16% in four studies [32, 35, 43, 45], respectively, whereas other studies
[38, 39, 46] found this to decrease the risk by 75%, 74% and 80%, respectively.
Patients’ insurance was reported as a risk/protective factor in five studies: four in the USA and one in
Europe [19, 31, 35, 38, 40] (tables S2 and S3). Smaller hospital size (<100 beds) and fewer doctors were
reported as significant readmission risk factors with 2.27-fold and 67% increased odds of readmission,
respectively [21]. Staying in medium-sized hospitals compared to large hospitals decreased the odds of
readmission by 5% [35]. Those who had outpatient visits were 44% less likely to be readmitted [46].
Discussion
This study is the first to systematically examine and summarise risk factors for all-cause hospital
readmission following an initial admission for exacerbation of COPD. Other reviews [14] have only
considered readmissions directly due to COPD, at variance with a patient-centred and holistic approach to
healthcare and clinical outcomes. Our main findings indicate that comorbidities, previous exacerbations
and hospitalisations, and increased LOS were the major risk factors for both 30- and 90-day readmission.
Our meta-analysis revealed that heart failure, renal failure, depression, and alcohol use were all associated
with an increased risk of 30-day all-cause COPD readmission, whereas being female was a protective
factor.
Many comorbidities were significant risk factors for 30- and 90-day readmission, including mental health
disorders. A possible explanation for this might be a lack of adequate interventions that extend beyond
COPD-specific treatment during the initial hospitalisation. There is an ongoing debate as to whether
underlying comorbidities are the main reason for higher readmission rates [13]; our results highlight that
this is indeed a key risk.
Three comorbidities (heart failure, renal failure and depression) and alcohol use were found to be
frequently reported risks. This differs from the findings presented in a systematic review concerning
readmission due only to COPD, in which no single comorbidity was reported to be associated with
readmission risk [14]. Focusing effort in addressing multi-morbidity and social determinants of health
may be one method to reduce the burden of readmissions following a hospitalised exacerbation of COPD
[13].
Consistently with the literature, our results show that previous exacerbations and hospitalisations are
significantly associated with all-cause readmission [14]. Exacerbations have been found to negatively affect
health status, increase costs and ultimately increase the risk of death [49, 50]. Indeed, frequent
exacerbations have been reported as a distinct susceptibility phenotype, which may support the targeting
of such patients with effective preventive strategies [51]. There are many cost-effective interventions such
as inhalers and pulmonary rehabilitation that could reduce exacerbations and related hospitalisations.
However, such interventions are not always effective due to inadequate inhaler technique or poor
adherence [52]. A recent meta-analysis found that the frequency of COPD exacerbations has decreased
over the past two decades, independently of major prognostic factors [53]. This probably indicates that
healthcare improvements over time have resulted in lower rates of exacerbation in the placebo groups of
clinical trials. Adopting appropriate care and preventive approaches could also have a favourable effect on
COPD readmissions.
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Increased LOS was found to be a significant risk factor for readmission within 30 days in nine studies, and
within 90 days in two studies. This may be because of increased severity of disease or, again, the presence
of comorbidities. LOS was not found to be a significant risk factor for COPD-related readmission in a
previous systematic review that included 17 studies [14]. LOS could be used to recognise patients with
higher readmission risk and who may benefit from supported discharge, early COPD community support
and/or earlier follow-up following initial discharge. We could not perform a meta-analysis on the LOS
because the reporting comparisons across the studies were inconsistent.
Different tools have been used to assess COPD severity, such as the LACE index, APR-DRG and COPD
complexity tool [19, 20, 22]. As expected, patients with increased disease severity had higher odds of
30-day readmission, independently of the method of measuring disease severity. There are other scores
that have been developed to assess readmission risk in COPD, such as CODEX and PEARL [17, 27].
However, there is no 30-day specific risk prediction tool to identify patients at high risk of all-cause COPD
readmission. Thus, to date, there is one tool for 90-day COPD readmissions, the PEARL score (previous
admissions, dyspnoea (eMRCD score), age, right-sided and left-sided heart failure) and notably this does
not include comorbidities other than heart failure [27]. According to a recent systematic review on models
that predict exacerbations, no existing models meet the requirements for risk-stratified treatment for
personalised COPD care [54]. In order to move personalised COPD medicine forward, a more harmonised
approach to developing and validating high-quality prediction models is needed.
We identified several patient, behavioural and social risk factors associated with an increased risk of
30-day readmission. Former smokers compared to those who had never smoked or were passive smokers,
those with low socioeconomic status and unmarried patients were identified as at significant risk for
30-day readmission [31, 38, 46]. Underweight patients and weight loss were also found to increase the risk
of readmission in two studies [31, 45]; being obese was reported to be a significant protective factor in two
studies [31, 35]. Six studies discussed alcohol use [31, 34, 35, 44–46], five of which found it as a significant
risk factor for all-cause COPD readmission. This was not found to be an independent marker for
COPD-related readmission [14]. Our results support previous finding that identified alcohol use as a
significant predictor of COPD mortality [55].
Chronic use of systemic corticosteroids was a risk factor for both 30- and 90-day readmission [18, 38].
This has been reported by BAHADORI and FITZGERALD [14] considering COPD-specific readmission. This
might be explained by side-effects such as muscle weaknesses, or use of these drugs in people with more
severe COPD. Low physical activity was found to be an important risk factor for 30-day readmission in
three studies [24, 38, 39], with those who were more active being less likely to be readmitted. Indeed,
physical inactivity has been associated with all-cause mortality and hospitalisation [56]. Although there is
a difference between physical activity and pulmonary rehabilitation, existing research on early pulmonary
rehabilitation post-exacerbation did not show a reduction in readmission risk [57]. Further research
considering interventions to improve or maintain physical activity in the immediate post-discharge period
following COPD exacerbation is needed to test whether this can improve outcomes and reduce the risk of
readmission.
Discharge destination was associated with 30-day readmission in nine studies. When patients were
discharged to a skilled nursing facility or home with care, the odds of readmission increased in five studies
[19, 32, 35, 43, 45]. It is likely that those patients were more unwell or frail with more comorbidities than
those discharged home and thus more likely to be readmitted. However, the quality of care could affect
readmission as demonstrated in other studies [38, 39, 46]. In addition, we found that those with US
Medicaid and Medicare cover had higher odds of readmission within 30 days than those with private
insurance or self-funding; Medicaid and Medicare have more barriers to primary care than those with
other types of insurance, which may also lead to increased readmissions [58].
Our work has a number of distinguishing aspects from existing work, which had considered only
COPD-related readmission [14]. To our knowledge, the present study is the first to systematically evaluate
existing literature with a focus on risk factors for all-cause readmissions. We conducted a meta-analysis
using a random-effects model to calculate the adjusted odds ratios on the most frequently reported risk/
protective factors to account for observed heterogeneity among studies. This increased the generalisability
of our findings, as heterogeneity was addressed by incorporating between-study variability of effect sizes.
This review has some limitations. First, we excluded two non-English studies. Secondly, study
heterogeneity exists in location, setting, design and reported risk factors; therefore, our meta-analysis
results were restricted to 14 studies in total, but these studies were representative of the target population.
Thirdly, we acknowledge the heterogeneity of the diagnosis of COPD exacerbations between studies.
Exacerbation of COPD is a clinical diagnosis of exclusion and all patients were being managed by their
clinicians as having that diagnosis. Despite the limitations of this approach, it remains the gold standard
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diagnosis. As is common in studies of hospitalised COPD exacerbations, not all patients had confirmatory
spirometry available to clinicians at the time of management. Finally, our meta-analysis was conducted on
summary data, not individual patient data.
Our review has important clinical implications. It summarises current evidence to inform guideline
developers about the importance of carefully reviewing the discharge processes and to ensure that
comorbidities are fully managed along with routine COPD management. Clinicians should devote more
resources to identify and manage patients with COPD at a high risk of hospital readmission and to
promote physical activity and follow-up in the immediate post-discharge period. Not all the risk factors
for readmission that we have identified are modifiable and therefore future research should focus on
developing robust risk models to predict patients with COPD at high risk of potentially avoidable hospital
readmission, with interventions tested to mitigate modifiable risk to improve outcomes for patients and
health services.
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